William Fantegrossi
Concepts (343)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
N-Methyl-3,4-methylenedioxyamphetamine | 22 | 2024 | 37 | 6.650 |
Why?
| Hallucinogens | 22 | 2023 | 65 | 5.120 |
Why?
| Cannabinoids | 16 | 2025 | 105 | 4.970 |
Why?
| Central Nervous System Stimulants | 16 | 2023 | 209 | 4.500 |
Why?
| Indoles | 21 | 2025 | 278 | 4.140 |
Why?
| Pyrrolidines | 10 | 2020 | 67 | 4.130 |
Why?
| Benzodioxoles | 9 | 2020 | 40 | 4.090 |
Why?
| Motor Activity | 16 | 2024 | 225 | 4.080 |
Why?
| Naphthalenes | 16 | 2025 | 121 | 3.960 |
Why?
| Receptor, Cannabinoid, CB1 | 16 | 2022 | 123 | 3.870 |
Why?
| Conditioning, Operant | 15 | 2024 | 109 | 3.740 |
Why?
| Locomotion | 9 | 2024 | 84 | 3.400 |
Why?
| Behavior, Animal | 17 | 2016 | 178 | 3.010 |
Why?
| Cannabinoid Receptor Agonists | 10 | 2025 | 51 | 2.930 |
Why?
| Animals | 82 | 2025 | 13124 | 2.660 |
Why?
| Mice | 48 | 2025 | 5687 | 2.370 |
Why?
| Substance-Related Disorders | 13 | 2024 | 611 | 2.330 |
Why?
| Dose-Response Relationship, Drug | 31 | 2023 | 1372 | 2.220 |
Why?
| Discrimination Learning | 8 | 2020 | 64 | 2.050 |
Why?
| Body Temperature Regulation | 4 | 2020 | 22 | 1.830 |
Why?
| Cocaine | 12 | 2020 | 182 | 1.800 |
Why?
| Indazoles | 8 | 2025 | 46 | 1.760 |
Why?
| Drug Tolerance | 4 | 2019 | 60 | 1.720 |
Why?
| Designer Drugs | 6 | 2016 | 22 | 1.710 |
Why?
| Alkaloids | 5 | 2023 | 28 | 1.680 |
Why?
| Hypothermia | 4 | 2022 | 36 | 1.600 |
Why?
| Amphetamines | 6 | 2023 | 29 | 1.570 |
Why?
| Temperature | 3 | 2023 | 162 | 1.520 |
Why?
| Male | 57 | 2025 | 25907 | 1.480 |
Why?
| Phencyclidine | 2 | 2024 | 35 | 1.480 |
Why?
| Rats, Sprague-Dawley | 9 | 2024 | 1585 | 1.430 |
Why?
| Receptor, Serotonin, 5-HT2A | 7 | 2014 | 13 | 1.340 |
Why?
| Impulsive Behavior | 2 | 2020 | 76 | 1.290 |
Why?
| Receptor, Cannabinoid, CB2 | 5 | 2018 | 57 | 1.270 |
Why?
| Rats | 19 | 2024 | 3292 | 1.240 |
Why?
| Analgesics, Opioid | 6 | 2025 | 575 | 1.240 |
Why?
| Narcotic Antagonists | 5 | 2025 | 136 | 1.210 |
Why?
| Dopamine | 8 | 2019 | 175 | 1.180 |
Why?
| Self Administration | 15 | 2020 | 97 | 1.090 |
Why?
| Dopamine Uptake Inhibitors | 7 | 2020 | 59 | 1.070 |
Why?
| Piperidines | 13 | 2025 | 99 | 1.060 |
Why?
| Fentanyl | 2 | 2025 | 36 | 1.050 |
Why?
| Telemetry | 4 | 2020 | 29 | 1.010 |
Why?
| Phenethylamines | 5 | 2014 | 9 | 1.000 |
Why?
| Naloxone | 2 | 2025 | 81 | 1.000 |
Why?
| Valine | 3 | 2022 | 57 | 0.990 |
Why?
| Serotonin | 4 | 2018 | 151 | 0.990 |
Why?
| Naltrexone | 4 | 2021 | 59 | 0.960 |
Why?
| Head Movements | 2 | 2014 | 6 | 0.940 |
Why?
| Tryptamines | 4 | 2014 | 10 | 0.920 |
Why?
| Respiratory Insufficiency | 2 | 2025 | 117 | 0.890 |
Why?
| Serotonin 5-HT2 Receptor Agonists | 4 | 2021 | 7 | 0.870 |
Why?
| Body Temperature | 8 | 2017 | 67 | 0.840 |
Why?
| Convulsants | 2 | 2022 | 7 | 0.830 |
Why?
| Psychoses, Substance-Induced | 2 | 2024 | 7 | 0.830 |
Why?
| Cyclohexylamines | 2 | 2024 | 4 | 0.810 |
Why?
| Brain | 10 | 2025 | 1319 | 0.780 |
Why?
| Biogenic Monoamines | 4 | 2017 | 13 | 0.770 |
Why?
| Receptors, Opioid, mu | 4 | 2018 | 46 | 0.770 |
Why?
| Cannabinoid Receptor Antagonists | 3 | 2020 | 16 | 0.770 |
Why?
| Stereoisomerism | 13 | 2016 | 104 | 0.770 |
Why?
| Reinforcement Schedule | 7 | 2020 | 76 | 0.770 |
Why?
| Quinuclidines | 2 | 2019 | 40 | 0.760 |
Why?
| Methamphetamine | 7 | 2020 | 194 | 0.750 |
Why?
| Choice Behavior | 2 | 2019 | 83 | 0.750 |
Why?
| Laboratories | 1 | 2021 | 19 | 0.740 |
Why?
| Seizures | 3 | 2022 | 195 | 0.740 |
Why?
| Neurotransmitter Uptake Inhibitors | 2 | 2018 | 6 | 0.730 |
Why?
| Serotonin Antagonists | 8 | 2009 | 35 | 0.700 |
Why?
| Alcoholism | 2 | 2021 | 235 | 0.700 |
Why?
| Ethanol | 3 | 2021 | 336 | 0.670 |
Why?
| Stereotyped Behavior | 1 | 2019 | 17 | 0.670 |
Why?
| Receptors, Opioid, delta | 2 | 2018 | 25 | 0.670 |
Why?
| Serotonin Agents | 4 | 2020 | 13 | 0.660 |
Why?
| Alcohol Drinking | 1 | 2021 | 227 | 0.660 |
Why?
| Adamantane | 4 | 2020 | 24 | 0.650 |
Why?
| Piperazines | 5 | 2007 | 119 | 0.640 |
Why?
| Enzyme Inhibitors | 3 | 2019 | 377 | 0.640 |
Why?
| Macaca mulatta | 14 | 2011 | 97 | 0.620 |
Why?
| Glutamic Acid | 2 | 2018 | 113 | 0.620 |
Why?
| Dopamine Plasma Membrane Transport Proteins | 3 | 2023 | 42 | 0.610 |
Why?
| Fluorobenzenes | 8 | 2014 | 22 | 0.600 |
Why?
| Drug Interactions | 5 | 2021 | 206 | 0.600 |
Why?
| Morphine Derivatives | 1 | 2018 | 27 | 0.600 |
Why?
| Fever | 2 | 2017 | 112 | 0.600 |
Why?
| Vaccination | 1 | 2020 | 280 | 0.590 |
Why?
| Cyclohexanones | 1 | 2017 | 5 | 0.580 |
Why?
| Cannabis | 1 | 2019 | 146 | 0.540 |
Why?
| Brain Chemistry | 2 | 2007 | 69 | 0.520 |
Why?
| Avoidance Learning | 2 | 2014 | 14 | 0.500 |
Why?
| Receptor, Serotonin, 5-HT2C | 3 | 2010 | 5 | 0.480 |
Why?
| Visceral Pain | 1 | 2014 | 2 | 0.460 |
Why?
| Appetite | 1 | 2014 | 15 | 0.460 |
Why?
| Morphine Dependence | 1 | 2014 | 11 | 0.460 |
Why?
| Disease Models, Animal | 5 | 2023 | 1436 | 0.450 |
Why?
| Structure-Activity Relationship | 6 | 2023 | 395 | 0.440 |
Why?
| Aporphines | 3 | 2016 | 4 | 0.440 |
Why?
| Substance Withdrawal Syndrome | 3 | 2019 | 168 | 0.420 |
Why?
| Receptor, Serotonin, 5-HT1A | 3 | 2007 | 5 | 0.420 |
Why?
| Humans | 29 | 2023 | 50503 | 0.400 |
Why?
| Fenclonine | 2 | 2017 | 6 | 0.400 |
Why?
| Physical Conditioning, Animal | 1 | 2012 | 57 | 0.400 |
Why?
| Microsomes, Liver | 4 | 2020 | 183 | 0.380 |
Why?
| Pain | 2 | 2013 | 387 | 0.360 |
Why?
| Head | 1 | 2010 | 70 | 0.340 |
Why?
| Movement | 1 | 2010 | 82 | 0.340 |
Why?
| Receptors, Serotonin | 3 | 2007 | 29 | 0.320 |
Why?
| Analgesics, Non-Narcotic | 2 | 2025 | 117 | 0.320 |
Why?
| Pain Measurement | 2 | 2013 | 270 | 0.320 |
Why?
| Ketanserin | 4 | 2014 | 9 | 0.280 |
Why?
| Lysergic Acid Diethylamide | 4 | 2007 | 7 | 0.270 |
Why?
| Random Allocation | 2 | 2020 | 289 | 0.270 |
Why?
| Reaction Time | 4 | 2018 | 214 | 0.270 |
Why?
| Crowding | 2 | 2004 | 14 | 0.270 |
Why?
| 5-Methoxytryptamine | 1 | 2006 | 2 | 0.260 |
Why?
| Microglia | 1 | 2007 | 136 | 0.260 |
Why?
| Serotonin Receptor Agonists | 1 | 2005 | 14 | 0.250 |
Why?
| Diterpenes | 1 | 2005 | 30 | 0.250 |
Why?
| Receptors, Opioid, kappa | 1 | 2005 | 39 | 0.250 |
Why?
| Corpus Striatum | 2 | 2019 | 51 | 0.250 |
Why?
| Neurotoxicity Syndromes | 1 | 2006 | 46 | 0.250 |
Why?
| Imines | 1 | 2025 | 14 | 0.250 |
Why?
| Psychotropic Drugs | 1 | 2005 | 76 | 0.240 |
Why?
| Benzoquinones | 1 | 2025 | 32 | 0.240 |
Why?
| Cognition | 2 | 2024 | 346 | 0.240 |
Why?
| Receptors, Neurotensin | 1 | 2004 | 7 | 0.240 |
Why?
| Neurotensin | 1 | 2004 | 17 | 0.240 |
Why?
| Phencyclidine Abuse | 1 | 2024 | 1 | 0.230 |
Why?
| Tetrabenazine | 1 | 2004 | 12 | 0.230 |
Why?
| Opioid-Related Disorders | 2 | 2019 | 393 | 0.230 |
Why?
| Norepinephrine Plasma Membrane Transport Proteins | 1 | 2023 | 8 | 0.230 |
Why?
| Receptors, Cannabinoid | 2 | 2014 | 16 | 0.220 |
Why?
| Hypotension | 1 | 2004 | 63 | 0.220 |
Why?
| Amines | 1 | 2004 | 41 | 0.220 |
Why?
| Amphetamine-Related Disorders | 2 | 2020 | 93 | 0.220 |
Why?
| Ketamine | 1 | 2024 | 59 | 0.220 |
Why?
| Peptide Fragments | 1 | 2004 | 209 | 0.220 |
Why?
| Binding, Competitive | 4 | 2013 | 94 | 0.220 |
Why?
| Central Nervous System Depressants | 2 | 2021 | 80 | 0.220 |
Why?
| Serotonin Plasma Membrane Transport Proteins | 1 | 2023 | 45 | 0.220 |
Why?
| Food | 2 | 2009 | 66 | 0.220 |
Why?
| Serotonin 5-HT2 Receptor Antagonists | 2 | 2014 | 9 | 0.210 |
Why?
| Metabolic Networks and Pathways | 2 | 2020 | 92 | 0.210 |
Why?
| Social Isolation | 1 | 2003 | 28 | 0.210 |
Why?
| Cytochrome P-450 CYP3A | 2 | 2020 | 77 | 0.210 |
Why?
| Pentylenetetrazole | 1 | 2022 | 9 | 0.200 |
Why?
| Diazepam | 1 | 2022 | 17 | 0.200 |
Why?
| Analysis of Variance | 2 | 2017 | 552 | 0.200 |
Why?
| Data Interpretation, Statistical | 3 | 2007 | 162 | 0.200 |
Why?
| Tremor | 1 | 2022 | 11 | 0.200 |
Why?
| Acetaminophen | 1 | 2025 | 276 | 0.200 |
Why?
| Amides | 1 | 2022 | 35 | 0.200 |
Why?
| Fluoxetine | 2 | 2017 | 42 | 0.200 |
Why?
| Carrier Proteins | 1 | 2023 | 298 | 0.200 |
Why?
| Benzodiazepines | 1 | 2022 | 70 | 0.190 |
Why?
| Rats, Inbred F344 | 3 | 2007 | 197 | 0.190 |
Why?
| Rats, Long-Evans | 1 | 2021 | 26 | 0.190 |
Why?
| Liver | 2 | 2025 | 1132 | 0.190 |
Why?
| Alcohol Deterrents | 1 | 2021 | 11 | 0.190 |
Why?
| Injections, Intraperitoneal | 3 | 2014 | 59 | 0.190 |
Why?
| Housing, Animal | 1 | 2021 | 15 | 0.190 |
Why?
| Electroencephalography | 1 | 2022 | 304 | 0.180 |
Why?
| Chromatography, High Pressure Liquid | 3 | 2020 | 326 | 0.180 |
Why?
| Dopamine Agents | 2 | 2016 | 18 | 0.170 |
Why?
| Artificial Gene Fusion | 1 | 2020 | 6 | 0.170 |
Why?
| Immunoglobulin Fc Fragments | 1 | 2020 | 11 | 0.170 |
Why?
| Microsomes | 1 | 2020 | 35 | 0.170 |
Why?
| Spiro Compounds | 2 | 2010 | 8 | 0.170 |
Why?
| Molecular Structure | 6 | 2014 | 296 | 0.170 |
Why?
| Single-Chain Antibodies | 1 | 2020 | 21 | 0.170 |
Why?
| Narcotics | 2 | 1998 | 112 | 0.170 |
Why?
| Adrenergic Uptake Inhibitors | 1 | 2019 | 15 | 0.170 |
Why?
| Rodentia | 1 | 2020 | 16 | 0.170 |
Why?
| Psychopharmacology | 1 | 2019 | 5 | 0.170 |
Why?
| GTP-Binding Proteins | 2 | 2017 | 91 | 0.160 |
Why?
| Catalepsy | 1 | 2019 | 9 | 0.160 |
Why?
| Nociception | 1 | 2019 | 13 | 0.160 |
Why?
| Genetic Therapy | 1 | 2020 | 120 | 0.160 |
Why?
| Female | 14 | 2025 | 27081 | 0.160 |
Why?
| Morpholines | 2 | 2017 | 66 | 0.160 |
Why?
| Taste | 1 | 2018 | 29 | 0.150 |
Why?
| Cytochrome P-450 Enzyme System | 2 | 2017 | 194 | 0.150 |
Why?
| Time Factors | 2 | 2019 | 2935 | 0.150 |
Why?
| Fetus | 1 | 2019 | 183 | 0.150 |
Why?
| alpha-Methyltyrosine | 1 | 2017 | 4 | 0.150 |
Why?
| Propiophenones | 1 | 2017 | 2 | 0.140 |
Why?
| Phthalimides | 1 | 2017 | 4 | 0.140 |
Why?
| Reproducibility of Results | 1 | 2021 | 1197 | 0.140 |
Why?
| Animals, Newborn | 2 | 2019 | 363 | 0.140 |
Why?
| Buprenorphine | 1 | 2019 | 145 | 0.140 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2019 | 182 | 0.140 |
Why?
| Benzoxazines | 1 | 2017 | 17 | 0.140 |
Why?
| Mice, Inbred Strains | 3 | 2012 | 160 | 0.130 |
Why?
| Positron-Emission Tomography | 2 | 2009 | 292 | 0.130 |
Why?
| Oxidation-Reduction | 4 | 2020 | 316 | 0.130 |
Why?
| Tandem Mass Spectrometry | 3 | 2014 | 238 | 0.130 |
Why?
| Serotonin 5-HT1 Receptor Agonists | 1 | 2016 | 4 | 0.130 |
Why?
| Recombinant Proteins | 4 | 2020 | 476 | 0.130 |
Why?
| Blood-Brain Barrier | 1 | 2016 | 47 | 0.130 |
Why?
| Schizophrenia | 1 | 2018 | 258 | 0.130 |
Why?
| Marijuana Abuse | 1 | 2018 | 154 | 0.130 |
Why?
| Pyridines | 2 | 2007 | 131 | 0.120 |
Why?
| Cerebral Cortex | 2 | 2007 | 197 | 0.120 |
Why?
| Blood Pressure | 1 | 2018 | 531 | 0.120 |
Why?
| Injections, Intravenous | 2 | 2006 | 137 | 0.120 |
Why?
| Psychomotor Performance | 2 | 2013 | 130 | 0.120 |
Why?
| Endothelial Cells | 1 | 2016 | 258 | 0.110 |
Why?
| Drug Synergism | 2 | 2013 | 151 | 0.110 |
Why?
| Antipsychotic Agents | 1 | 2016 | 233 | 0.110 |
Why?
| Administration, Inhalation | 1 | 2014 | 112 | 0.110 |
Why?
| Urinalysis | 1 | 2014 | 33 | 0.110 |
Why?
| Membranes | 1 | 2013 | 16 | 0.110 |
Why?
| Microdialysis | 2 | 2010 | 19 | 0.100 |
Why?
| Metabolomics | 1 | 2013 | 135 | 0.100 |
Why?
| Kinetics | 3 | 2020 | 623 | 0.100 |
Why?
| Metabolic Detoxication, Phase I | 1 | 2011 | 11 | 0.090 |
Why?
| Pyrazoles | 1 | 2012 | 111 | 0.090 |
Why?
| Oxalates | 1 | 2011 | 11 | 0.090 |
Why?
| Receptors, sigma | 1 | 2011 | 17 | 0.090 |
Why?
| Ethylamines | 1 | 2010 | 3 | 0.090 |
Why?
| Infusions, Intravenous | 2 | 2004 | 213 | 0.090 |
Why?
| Aminopyridines | 1 | 2010 | 15 | 0.090 |
Why?
| Glutathione | 2 | 2025 | 299 | 0.090 |
Why?
| Cricetulus | 3 | 2017 | 97 | 0.090 |
Why?
| CHO Cells | 3 | 2017 | 118 | 0.090 |
Why?
| Prolactin | 1 | 2010 | 44 | 0.090 |
Why?
| Amphetamine | 1 | 2010 | 38 | 0.090 |
Why?
| Tissue Distribution | 2 | 2013 | 166 | 0.080 |
Why?
| Models, Animal | 2 | 2011 | 227 | 0.080 |
Why?
| Cells, Cultured | 1 | 2013 | 1571 | 0.080 |
Why?
| Saimiri | 1 | 2009 | 2 | 0.080 |
Why?
| Nortropanes | 1 | 2009 | 3 | 0.080 |
Why?
| Sulfonamides | 1 | 2010 | 126 | 0.080 |
Why?
| Electrochemical Techniques | 1 | 2009 | 11 | 0.080 |
Why?
| Tropanes | 1 | 2009 | 4 | 0.080 |
Why?
| Fluorine Radioisotopes | 1 | 2009 | 24 | 0.080 |
Why?
| Receptors, Opioid | 1 | 2009 | 18 | 0.080 |
Why?
| Polymorphism, Genetic | 2 | 2020 | 180 | 0.080 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2009 | 244 | 0.080 |
Why?
| Legislation, Medical | 1 | 2008 | 3 | 0.070 |
Why?
| Imidazoles | 1 | 2009 | 127 | 0.070 |
Why?
| Neostriatum | 1 | 2007 | 10 | 0.070 |
Why?
| Isoquinolines | 1 | 2007 | 25 | 0.070 |
Why?
| Primates | 1 | 2007 | 19 | 0.070 |
Why?
| Mice, Inbred C57BL | 2 | 2025 | 1808 | 0.070 |
Why?
| Ligands | 3 | 2013 | 203 | 0.070 |
Why?
| Cues | 1 | 2007 | 51 | 0.070 |
Why?
| Cocaine-Related Disorders | 1 | 2009 | 209 | 0.070 |
Why?
| Generalization, Stimulus | 1 | 2005 | 5 | 0.060 |
Why?
| Benzeneacetamides | 1 | 2005 | 12 | 0.060 |
Why?
| Diterpenes, Clerodane | 1 | 2005 | 20 | 0.060 |
Why?
| Premedication | 1 | 2005 | 17 | 0.060 |
Why?
| Racemases and Epimerases | 1 | 2005 | 17 | 0.060 |
Why?
| Body Weight | 1 | 2007 | 517 | 0.060 |
Why?
| Pregnancy | 2 | 2025 | 2452 | 0.060 |
Why?
| Reactive Oxygen Species | 2 | 2018 | 409 | 0.060 |
Why?
| Cognition Disorders | 1 | 2006 | 213 | 0.060 |
Why?
| Protein Binding | 2 | 2020 | 654 | 0.060 |
Why?
| Tritium | 1 | 2004 | 47 | 0.060 |
Why?
| Electrochemistry | 1 | 2004 | 25 | 0.060 |
Why?
| Radioligand Assay | 1 | 2004 | 46 | 0.060 |
Why?
| Tomography, Emission-Computed | 1 | 2004 | 53 | 0.060 |
Why?
| N,N-Dimethyltryptamine | 1 | 2004 | 1 | 0.060 |
Why?
| Mescaline | 1 | 2004 | 3 | 0.060 |
Why?
| Prazosin | 1 | 2004 | 10 | 0.060 |
Why?
| Biomedical Research | 1 | 2007 | 244 | 0.060 |
Why?
| Adrenergic alpha-Antagonists | 1 | 2004 | 27 | 0.060 |
Why?
| ROC Curve | 1 | 2004 | 226 | 0.050 |
Why?
| Analgesics | 1 | 2004 | 116 | 0.050 |
Why?
| Risk Assessment | 1 | 2008 | 1270 | 0.050 |
Why?
| Lethal Dose 50 | 1 | 2003 | 12 | 0.050 |
Why?
| Brain Mapping | 1 | 2004 | 225 | 0.050 |
Why?
| Drug Inverse Agonism | 2 | 2013 | 18 | 0.050 |
Why?
| Cold Temperature | 1 | 2003 | 44 | 0.050 |
Why?
| Cricetinae | 2 | 2013 | 188 | 0.050 |
Why?
| Chromatography, Liquid | 2 | 2014 | 231 | 0.050 |
Why?
| Hydroxylation | 2 | 2012 | 61 | 0.050 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2003 | 174 | 0.050 |
Why?
| Cytochrome P-450 CYP2D6 | 1 | 2020 | 22 | 0.040 |
Why?
| Mice, Inbred BALB C | 1 | 2020 | 296 | 0.040 |
Why?
| Attitude | 1 | 2019 | 69 | 0.040 |
Why?
| Dependovirus | 1 | 2020 | 102 | 0.040 |
Why?
| Uridine Diphosphate Glucuronic Acid | 1 | 2019 | 9 | 0.040 |
Why?
| Intestines | 1 | 2020 | 172 | 0.040 |
Why?
| Malate Dehydrogenase | 1 | 2018 | 8 | 0.040 |
Why?
| Risk | 1 | 2019 | 324 | 0.040 |
Why?
| Glucuronosyltransferase | 1 | 2019 | 122 | 0.040 |
Why?
| Pharmacists | 1 | 2019 | 145 | 0.040 |
Why?
| Vascular Stiffness | 1 | 2018 | 20 | 0.040 |
Why?
| Sex Factors | 1 | 2020 | 712 | 0.040 |
Why?
| Cyclohexanols | 1 | 2017 | 21 | 0.040 |
Why?
| PC12 Cells | 1 | 2017 | 24 | 0.040 |
Why?
| United States | 1 | 2008 | 4955 | 0.030 |
Why?
| Cell Death | 1 | 2017 | 175 | 0.030 |
Why?
| Microvessels | 1 | 2016 | 30 | 0.030 |
Why?
| Receptors, Dopamine D4 | 1 | 2016 | 8 | 0.030 |
Why?
| Necrosis | 1 | 2016 | 174 | 0.030 |
Why?
| Cattle | 1 | 2016 | 205 | 0.030 |
Why?
| HEK293 Cells | 1 | 2016 | 213 | 0.030 |
Why?
| Cross-Sectional Studies | 1 | 2019 | 1610 | 0.030 |
Why?
| Vesicular Monoamine Transport Proteins | 1 | 2014 | 47 | 0.030 |
Why?
| Nitric Oxide | 1 | 2016 | 259 | 0.030 |
Why?
| MicroRNAs | 1 | 2018 | 344 | 0.030 |
Why?
| Pentanones | 1 | 2013 | 7 | 0.030 |
Why?
| Paper | 1 | 2013 | 15 | 0.030 |
Why?
| Capsules | 1 | 2013 | 28 | 0.030 |
Why?
| Powders | 1 | 2013 | 22 | 0.030 |
Why?
| Methylamines | 1 | 2013 | 17 | 0.030 |
Why?
| Mitochondria | 1 | 2017 | 399 | 0.030 |
Why?
| Solid Phase Extraction | 1 | 2013 | 12 | 0.030 |
Why?
| Tablets | 1 | 2013 | 31 | 0.030 |
Why?
| Arkansas | 1 | 2019 | 1985 | 0.030 |
Why?
| Conditioning, Classical | 1 | 2013 | 33 | 0.030 |
Why?
| Drug Design | 1 | 2013 | 119 | 0.030 |
Why?
| Cell Proliferation | 1 | 2016 | 985 | 0.020 |
Why?
| Drug Partial Agonism | 1 | 2012 | 6 | 0.020 |
Why?
| Drug Antagonism | 1 | 2012 | 7 | 0.020 |
Why?
| Glucuronidase | 1 | 2011 | 48 | 0.020 |
Why?
| Cell Membrane | 1 | 2012 | 246 | 0.020 |
Why?
| Drug Evaluation, Preclinical | 1 | 2011 | 145 | 0.020 |
Why?
| 3,4-Dihydroxyphenylacetic Acid | 1 | 2010 | 9 | 0.020 |
Why?
| Homovanillic Acid | 1 | 2010 | 11 | 0.020 |
Why?
| Extracellular Space | 1 | 2010 | 40 | 0.020 |
Why?
| Molecular Targeted Therapy | 1 | 2011 | 123 | 0.020 |
Why?
| Fluoroacetates | 1 | 2009 | 1 | 0.020 |
Why?
| Iodobenzenes | 1 | 2009 | 1 | 0.020 |
Why?
| Trifluoroacetic Acid | 1 | 2009 | 1 | 0.020 |
Why?
| Cyclization | 1 | 2009 | 5 | 0.020 |
Why?
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2009 | 8 | 0.020 |
Why?
| Appetite Depressants | 1 | 2009 | 9 | 0.020 |
Why?
| Receptors, Adrenergic, alpha-1 | 1 | 2009 | 15 | 0.020 |
Why?
| Alfentanil | 1 | 2009 | 2 | 0.020 |
Why?
| Capsaicin | 1 | 2009 | 16 | 0.020 |
Why?
| Central Nervous System Agents | 1 | 2009 | 11 | 0.020 |
Why?
| Benzimidazoles | 1 | 2009 | 48 | 0.020 |
Why?
| Pruritus | 1 | 2009 | 43 | 0.020 |
Why?
| Hot Temperature | 1 | 2009 | 198 | 0.020 |
Why?
| Problem Solving | 1 | 2006 | 43 | 0.020 |
Why?
| Memory | 1 | 2006 | 114 | 0.020 |
Why?
| Attention | 1 | 2006 | 172 | 0.020 |
Why?
| Learning | 1 | 2006 | 159 | 0.010 |
Why?
| Injections, Subcutaneous | 1 | 1998 | 52 | 0.010 |
Why?
| Decanoates | 1 | 1996 | 1 | 0.010 |
Why?
|
|
Fantegrossi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|